{"sent_idx": "67", "frame_idx": "28", "ev": "The addition of bevacizumab to chemoimmunotherapy was found to be safe, with no significant differences in severe adverse events between the 2 arms, other than an increase in non-fatal cardiovascular complications (33% vs 3%, p<0.003); none of the 7 cases of hypertension presented as an hypertensive emergency, and they all resolved with non-urgent medical management; the 2 cases of CHF and the 1 case of myocarditis all occurred in patients with pre-existing heart dysfunction who had discontinued their home medications, and resolved with non-urgent medical management; the only grade 4 cardiovascular complication was a torsade de pointe, which occurred as a peri-surgical complication in a patient with pre-existing aortic aneurysm, developing an aortic dissection requiring surgical intervention.", "icos": [["1", "chemoimmunotherapy", "bevacizumab", "hypertension"]], "sample": "x"}
{"sent_idx": "67", "frame_idx": "29", "ev": "The addition of bevacizumab to chemoimmunotherapy was found to be safe, with no significant differences in severe adverse events between the 2 arms, other than an increase in non-fatal cardiovascular complications (33% vs 3%, p<0.003); none of the 7 cases of hypertension presented as an hypertensive emergency, and they all resolved with non-urgent medical management; the 2 cases of CHF and the 1 case of myocarditis all occurred in patients with pre-existing heart dysfunction who had discontinued their home medications, and resolved with non-urgent medical management; the only grade 4 cardiovascular complication was a torsade de pointe, which occurred as a peri-surgical complication in a patient with pre-existing aortic aneurysm, developing an aortic dissection requiring surgical intervention.", "icos": [["1", "chemoimmunotherapy", "bevacizumab", "non - fatal cardiovascular complications"]], "sample": "x"}
{"sent_idx": "67", "frame_idx": "30", "ev": "The addition of bevacizumab to chemoimmunotherapy was found to be safe, with no significant differences in severe adverse events between the 2 arms, other than an increase in non-fatal cardiovascular complications (33% vs 3%, p<0.003); none of the 7 cases of hypertension presented as an hypertensive emergency, and they all resolved with non-urgent medical management; the 2 cases of CHF and the 1 case of myocarditis all occurred in patients with pre-existing heart dysfunction who had discontinued their home medications, and resolved with non-urgent medical management; the only grade 4 cardiovascular complication was a torsade de pointe, which occurred as a peri-surgical complication in a patient with pre-existing aortic aneurysm, developing an aortic dissection requiring surgical intervention.", "icos": [["1", "chemoimmunotherapy", "bevacizumab", "hypertensive emergency"]], "sample": "x"}
{"sent_idx": "67", "frame_idx": "31", "ev": "The addition of bevacizumab to chemoimmunotherapy was found to be safe, with no significant differences in severe adverse events between the 2 arms, other than an increase in non-fatal cardiovascular complications (33% vs 3%, p<0.003); none of the 7 cases of hypertension presented as an hypertensive emergency, and they all resolved with non-urgent medical management; the 2 cases of CHF and the 1 case of myocarditis all occurred in patients with pre-existing heart dysfunction who had discontinued their home medications, and resolved with non-urgent medical management; the only grade 4 cardiovascular complication was a torsade de pointe, which occurred as a peri-surgical complication in a patient with pre-existing aortic aneurysm, developing an aortic dissection requiring surgical intervention.", "icos": [["1", "chemoimmunotherapy", "bevacizumab", "torsade"]], "sample": "x"}
{"sent_idx": "67", "frame_idx": "32", "ev": "The addition of bevacizumab to chemoimmunotherapy was found to be safe, with no significant differences in severe adverse events between the 2 arms, other than an increase in non-fatal cardiovascular complications (33% vs 3%, p<0.003); none of the 7 cases of hypertension presented as an hypertensive emergency, and they all resolved with non-urgent medical management; the 2 cases of CHF and the 1 case of myocarditis all occurred in patients with pre-existing heart dysfunction who had discontinued their home medications, and resolved with non-urgent medical management; the only grade 4 cardiovascular complication was a torsade de pointe, which occurred as a peri-surgical complication in a patient with pre-existing aortic aneurysm, developing an aortic dissection requiring surgical intervention.", "icos": [["1", "chemoimmunotherapy", "bevacizumab", "severe adverse events"]], "sample": "x"}
{"sent_idx": "67", "frame_idx": "33", "ev": "The addition of bevacizumab to chemoimmunotherapy was found to be safe, with no significant differences in severe adverse events between the 2 arms, other than an increase in non-fatal cardiovascular complications (33% vs 3%, p<0.003); none of the 7 cases of hypertension presented as an hypertensive emergency, and they all resolved with non-urgent medical management; the 2 cases of CHF and the 1 case of myocarditis all occurred in patients with pre-existing heart dysfunction who had discontinued their home medications, and resolved with non-urgent medical management; the only grade 4 cardiovascular complication was a torsade de pointe, which occurred as a peri-surgical complication in a patient with pre-existing aortic aneurysm, developing an aortic dissection requiring surgical intervention.", "icos": [["1", "chemoimmunotherapy", "bevacizumab", "cardiovascular complication"]], "sample": "x"}
{"sent_idx": "67", "frame_idx": "34", "ev": "The addition of bevacizumab to chemoimmunotherapy was found to be safe, with no significant differences in severe adverse events between the 2 arms, other than an increase in non-fatal cardiovascular complications (33% vs 3%, p<0.003); none of the 7 cases of hypertension presented as an hypertensive emergency, and they all resolved with non-urgent medical management; the 2 cases of CHF and the 1 case of myocarditis all occurred in patients with pre-existing heart dysfunction who had discontinued their home medications, and resolved with non-urgent medical management; the only grade 4 cardiovascular complication was a torsade de pointe, which occurred as a peri-surgical complication in a patient with pre-existing aortic aneurysm, developing an aortic dissection requiring surgical intervention.", "icos": [["1", "chemoimmunotherapy", "bevacizumab", "myocarditis"]], "sample": "x"}
{"sent_idx": "67", "frame_idx": "35", "ev": "The addition of bevacizumab to chemoimmunotherapy was found to be safe, with no significant differences in severe adverse events between the 2 arms, other than an increase in non-fatal cardiovascular complications (33% vs 3%, p<0.003); none of the 7 cases of hypertension presented as an hypertensive emergency, and they all resolved with non-urgent medical management; the 2 cases of CHF and the 1 case of myocarditis all occurred in patients with pre-existing heart dysfunction who had discontinued their home medications, and resolved with non-urgent medical management; the only grade 4 cardiovascular complication was a torsade de pointe, which occurred as a peri-surgical complication in a patient with pre-existing aortic aneurysm, developing an aortic dissection requiring surgical intervention.", "icos": [["1", "chemoimmunotherapy", "bevacizumab", "CHF"]], "sample": "x"}
{"sent_idx": "68", "frame_idx": "36", "ev": "Patients treated with PCR in combination with anti-VEGF therapy had a trend toward higher complete remission rate (54.5%) than patients receiving PCR alone (31.3%).", "icos": [["1", "PCR", "anti - VEGF therapy", "complete remission rate"]], "sample": "x"}
{"sent_idx": "7", "frame_idx": "1", "ev": "Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09).", "icos": [["0.99954647", "PCR - B", "PCR - B", "progression - free survival ( PFS )("], ["0.9994603", "PCR - B", "PCR", "progression - free survival ( PFS )("], ["0.9989317", "PCR - B", "PCR alone", "progression - free survival ( PFS )("], ["0.9983417", "PCR - B", "PCR in combination with bevacizumab ( PCR - B", "progression - free survival ( PFS )("], ["0.9966594", "PCR - B", "PCR in combination with bevacizumab", "progression - free survival ( PFS )("]], "sample": "c"}
{"sent_idx": "7", "frame_idx": "2", "ev": "Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09).", "icos": [["0.99958986", "PCR - B", "PCR - B", "complete remission ( CR ) rate"], ["0.999508", "PCR - B", "PCR", "complete remission ( CR ) rate"], ["0.9992731", "PCR - B", "PCR alone", "complete remission ( CR ) rate"], ["0.9990677", "PCR - B", "PCR in combination with bevacizumab ( PCR - B", "complete remission ( CR ) rate"], ["0.99841356", "PCR - B", "PCR in combination with bevacizumab", "complete remission ( CR ) rate"]], "sample": "c"}
{"sent_idx": "7", "frame_idx": "3", "ev": "Patients treated with PCR-B had a trend for a higher complete remission (CR) rate (54.5% vs 31.3%; p = 0.08), longer progression-free survival (PFS)(p = 0.06) and treatment-free survival (TFS)(p = 0.09).", "icos": [["0.99956495", "PCR - B", "PCR - B", "treatment - free survival ( TFS )("], ["0.9994661", "PCR - B", "PCR", "treatment - free survival ( TFS )("], ["0.9988932", "PCR - B", "PCR alone", "treatment - free survival ( TFS )("], ["0.99869883", "PCR - B", "PCR in combination with bevacizumab ( PCR - B", "treatment - free survival ( TFS )("], ["0.9976646", "PCR - B", "PCR in combination with bevacizumab", "treatment - free survival ( TFS )("]], "sample": "c"}
{"sent_idx": "8", "frame_idx": "4", "ev": "No differences in PFS and TFS by IGHV mutational status were observed with the addition of bevacizumab.", "icos": [["0.991321", "bevacizumab .", "PCR in combination with bevacizumab ( PCR - B", "PFS and TFS"], ["0.9817763", "bevacizumab .", "PCR", "PFS and TFS"], ["0.98067594", "bevacizumab .", "anti - VEGF antibody", "PFS and TFS"], ["0.98024255", "bevacizumab .", "Bevacizumab", "PFS and TFS"], ["0.98024255", "bevacizumab .", "bevacizumab", "PFS and TFS"]], "sample": "c"}
{"sent_idx": "38", "frame_idx": "8", "ev": "Twenty-three of 33 patients (69.7%) on PCR-B and 14 of 32 patients (44%) on PCR experienced at least one grade 3+ event at least possibly related to treatment (p=0.05).", "icos": [["0.99957746", "PCR - B", "PCR - B", "grade 3 + event"], ["0.99954814", "PCR - B", "PCR", "grade 3 + event"], ["0.999156", "PCR - B", "PCR alone", "grade 3 + event"], ["0.9983518", "PCR - B", "PCR in combination with bevacizumab ( PCR - B", "grade 3 + event"], ["0.99791163", "PCR - B", "PCR in combination with bevacizumab", "grade 3 + event"]], "sample": "c"}
{"sent_idx": "39", "frame_idx": "9", "ev": "Nine of 33 patients (27.3%) on PCR-B and 5 of 32 patients (15.6%) on PCR experienced a grade 4+ event at least possibly related to treatment (p=0.37).", "icos": [["0.9995679", "PCR - B", "PCR - B", "grade 4 + event"], ["0.99955124", "PCR - B", "PCR", "grade 4 + event"], ["0.9987399", "PCR - B", "PCR alone", "grade 4 + event"], ["0.9984268", "PCR - B", "PCR in combination with bevacizumab ( PCR - B", "grade 4 + event"], ["0.9977488", "PCR - B", "PCR in combination with bevacizumab", "grade 4 + event"]], "sample": "c"}
{"sent_idx": "50", "frame_idx": "17", "ev": "The median PFS has not yet been reached for PCR-B (Arm A) and was 34 months (95% confidence interval [CI], 23-52) for PCR alone (Arm B, p=0.06; Figure 1A).", "icos": [["0.9994886", "PCR - B", "PCR alone", "median PFS"], ["0.99941194", "PCR - B", "PCR - B", "median PFS"], ["0.9993777", "PCR - B", "PCR", "median PFS"], ["0.9991891", "PCR - B", "PCR in combination with bevacizumab", "median PFS"], ["0.9991478", "PCR - B", "PCR in combination with bevacizumab ( PCR - B", "median PFS"]], "sample": "c"}
{"sent_idx": "55", "frame_idx": "20", "ev": "While unmutated IGHV status determined a shorter PFS (p=0.02) and TFS (p=0.03) in the arm B, it did not affect survival when bevacizumab was added to PCR (Figure 2).", "icos": [["0.9979595", "bevacizumab", "PCR alone", "TFS"], ["0.99784243", "bevacizumab", "PCR", "TFS"], ["0.9973888", "bevacizumab", "chemoimmunotherapy", "TFS"], ["0.99703014", "bevacizumab", "Bevacizumab", "TFS"], ["0.99703014", "bevacizumab", "bevacizumab", "TFS"]], "sample": "c"}
{"sent_idx": "55", "frame_idx": "21", "ev": "While unmutated IGHV status determined a shorter PFS (p=0.02) and TFS (p=0.03) in the arm B, it did not affect survival when bevacizumab was added to PCR (Figure 2).", "icos": [["0.99720865", "bevacizumab", "PCR", "PFS"], ["0.9970325", "bevacizumab", "chemoimmunotherapy", "PFS"], ["0.9969584", "bevacizumab", "PCR alone", "PFS"], ["0.9941981", "bevacizumab", "chemotherapy", "PFS"], ["0.99404305", "bevacizumab", "PCR in combination with bevacizumab ( PCR - B", "PFS"]], "sample": "c"}
{"sent_idx": "70", "frame_idx": "37", "ev": "A higher (though not significant) MRD eradication rate was observed with the addition of bevacizumab, translating into longer PFS and TFS.", "icos": [["0.99730444", "bevacizumab", "Bevacizumab", "MRD eradication rate"], ["0.99730444", "bevacizumab", "bevacizumab", "MRD eradication rate"], ["0.9952624", "bevacizumab", "anti - VEGF therapy", "MRD eradication rate"], ["0.9942215", "bevacizumab", "chemoimmunotherapy", "MRD eradication rate"], ["0.9939855", "bevacizumab", "bevacizumab .", "MRD eradication rate"]], "sample": "c"}
{"sent_idx": "70", "frame_idx": "38", "ev": "A higher (though not significant) MRD eradication rate was observed with the addition of bevacizumab, translating into longer PFS and TFS.", "icos": [["0.9980718", "bevacizumab", "Bevacizumab", "PFS and TFS ."], ["0.9980718", "bevacizumab", "bevacizumab", "PFS and TFS ."], ["0.9975332", "bevacizumab", "anti - VEGF therapy", "PFS and TFS ."], ["0.9965926", "bevacizumab", "bevacizumab .", "PFS and TFS ."], ["0.99625945", "bevacizumab", "chemoimmunotherapy", "PFS and TFS ."]], "sample": "c"}
